1. Home
  2. PAR vs GERN Comparison

PAR vs GERN Comparison

Compare PAR & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAR
  • GERN
  • Stock Information
  • Founded
  • PAR 1968
  • GERN 1990
  • Country
  • PAR United States
  • GERN United States
  • Employees
  • PAR N/A
  • GERN N/A
  • Industry
  • PAR Office Equipment/Supplies/Services
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • PAR Miscellaneous
  • GERN Health Care
  • Exchange
  • PAR Nasdaq
  • GERN Nasdaq
  • Market Cap
  • PAR 2.8B
  • GERN 2.5B
  • IPO Year
  • PAR N/A
  • GERN 1996
  • Fundamental
  • Price
  • PAR $78.19
  • GERN $3.93
  • Analyst Decision
  • PAR Strong Buy
  • GERN Strong Buy
  • Analyst Count
  • PAR 8
  • GERN 10
  • Target Price
  • PAR $79.25
  • GERN $7.05
  • AVG Volume (30 Days)
  • PAR 430.6K
  • GERN 6.7M
  • Earning Date
  • PAR 11-08-2024
  • GERN 11-07-2024
  • Dividend Yield
  • PAR N/A
  • GERN N/A
  • EPS Growth
  • PAR N/A
  • GERN N/A
  • EPS
  • PAR N/A
  • GERN N/A
  • Revenue
  • PAR $453,986,000.00
  • GERN $29,480,000.00
  • Revenue This Year
  • PAR N/A
  • GERN $32,021.10
  • Revenue Next Year
  • PAR $17.85
  • GERN $298.14
  • P/E Ratio
  • PAR N/A
  • GERN N/A
  • Revenue Growth
  • PAR 49.11
  • GERN 9199.68
  • 52 Week Low
  • PAR $37.74
  • GERN $1.64
  • 52 Week High
  • PAR $82.24
  • GERN $5.34
  • Technical
  • Relative Strength Index (RSI)
  • PAR 59.84
  • GERN 46.32
  • Support Level
  • PAR $75.59
  • GERN $3.75
  • Resistance Level
  • PAR $79.26
  • GERN $4.05
  • Average True Range (ATR)
  • PAR 2.12
  • GERN 0.16
  • MACD
  • PAR -0.78
  • GERN -0.01
  • Stochastic Oscillator
  • PAR 36.02
  • GERN 39.13

About PAR PAR Technology Corporation

PAR Technology Corp together with its subsidiaries provides management technology solutions including software, hardware, and related services, integral to the point-of-sale infrastructure and task management, information gathering, assimilation, and communication services. It has two segments. The restaurant/ Retail segment provides point-of-sale and management technology solutions such as hardware, software, and integrated technical solutions to the restaurant and retail industries. The government segment provides intelligence, surveillance, and reconnaissance solutions and mission systems support. The company derives the majority of its revenues from the Restaurant/ Retail segment.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: